Aarti Pharmalabs achieves SBTi approval of GHG emission reduction targets
Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger
Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger
The discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons
Fluralaner invented by Nissan Chemical is the active pharmaceutical ingredient of BRAVECTO and EXZOLT,
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC) aims to accelerate the digital transformation of CMC development and manufacturing approaches
More than 40 types of Amyloid proteins are discovered till date
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
Women Health Card was launched exclusively for women health workers of the Tiruchirappalli City Corporation
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older
Subscribe To Our Newsletter & Stay Updated